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THIS ISSUE’S AUTHORS 
GREGORY S. BRIGHAM, Ph.D., is 
chief research officer and program direc­
tor at Maryhaven in Columbus, Ohio. 
Dr. Brigham is a psychologist with more 
than 20 years’ experience providing and 
managing drug abuse treatment. He is 
currently a Community Treatment Program 
principal investigator in the Ohio Valley 
Node of NIDA’s National Drug Abuse 
Treatment Clinical Trials Network. His 
research interests focus on developing 
and integrating empirically supported 
treatment improvements and 12-step 
recovery-oriented drug abuse treatment. 
DOUGLAS B. MARLOWE, J.D., Ph.D., 
is a senior scientist and director of the 
Section on Criminal Justice Research 
at the Treatment Research Institute, 
University of Pennsylvania in Philadel­
phia. Dr. Marlowe is a lawyer and clini­
cal psychologist whose research focuses 
on evaluating correctional diversion 
programs for substance-abusing offend­
ers. He is also associate editor (pending) 
of the Journal of Substance Abuse Treatment 
and serves on the Editorial Board of 
Criminal Justice & Behavior. 
THOMAS NIGHTINGALE, B.S., 
CASAC, is director of the Bureau of 
Addiction Treatment Centers overseeing 
New York State’s 13 addiction treatment 
facilities. He is the past director of the 
Norris Addiction Treatment Center in 
Rochester and the Van Dyke Addiction 
Treatment Center in Ovid, and he has 
worked in the addiction field for 28 years. 
STEVEN NOVAK, M.D., is medical 
director of the Norris Addiction Treatment 
Center in Rochester, New York, and he 
is cofounder of the Nicotine Awareness 
Coalition of Upstate New York. Dr. Novak 
has worked in the addiction field for 
12 years. 
PAULA D. RIGGS, M.D., is board cer­
tified in adult, child, and adolescent psy­
chiatry and has added qualifications in 
addiction psychiatry. She is associate pro­
fessor of psychiatry at the University of 
Colorado School of Medicine in Denver, 
where she is also director of psychiatric 
services for adolescents at the Addiction 
Research and Treatment Services. Dr. 
Riggs is also principal investigator of the 
Rocky Mountain Node of the National 
Drug Abuse Treatment Clinical Trials 
Network. 
STEVEN SCHWARTZ, Ph.D. (CAND.), 
CASAC, retired from his position as direc­
tor of the Stutzman Addiction Treatment 
Center in Buffalo, New York, after serv­
ing as center director for 35 years. He has 
worked in the field of addictions through­
out his career as an administrator and 
international consultant. 
JAMES R. SHARP, Ph.D., is a clinical 
psychologist and director of the Van Dyke 
Addiction Treatment Center in Ovid, 
New York. He has worked in the mental 
health and addiction fields for over 
25 years. 
& PANEL RESPONDENTS 
PATRICIA A. CHANDLER, M.D., is 
board certified in family practice and has 
been ASAM-certified since 1996.  Dr. 
Chandler has years of experience caring 
for adolescents in the primary care and 
sports medicine settings, and from 2000 
to 2002 she cared for patients with heroin 
addiction. Currently she is in private prac­
tice and is clinical assistant professor in 
the Department of Family Practice at the 
University of Texas Southwestern Medical 
Center in Dallas. 
ALLAN J. COHEN, M.A., MFT, is direc­
tor of research and development for Aegis 
Medical Systems in Canoga Park, California. 
Aegis operates 30 narcotic treatment pro­
grams, serving 5,000 patients daily. Mr. 
Cohen has worked with the criminal jus­
tice system over the past 25 years, most 
recently involving implementation of 
Proposition 36 services in the clinics and 
counties where Aegis Medical Systems 
operates. He has had extensive professional 
involvement with drug courts and parole 
and probation offices. Mr. Cohen has 
recently been deeply involved in NIDA’s 
Clinical Trials Network, blending research 
and clinical practice. 
LIRIO S. COVEY, M.D., is an associ­
ate professor of clinical psychology with 
the Department of Psychiatry at Columbia 
University in New York. She directs the 
Smoking Cessation Research Clinic at the 
Columbia-Presbyterian Medical Center 
campus, where she is the lead investiga­
tor on a NIDA-funded study of mainte­
nance pharmacotherapy for the preven­
tion of smoking relapse. Her current research 
projects also include studies on genetic 
factors in nicotine dependence, smoking 
cessation and relapse prevention in smok­
ers of racial/ethnic minority background, 
and tobacco cessation for mildly depen­
dent smokers. 
ROBERT F. FORMAN, Ph.D., is assis­
tant professor of psychology in psychia­
try at the University of Pennsylvania 
and director of technology transfer for 
Philadelphia’s Treatment Research Institute. 
Dr. Forman, who received his doctorate 
from Bryn Mawr College, has spent the 
majority of his career developing addic­
tion treatment services and products. He 
has served as a consultant to several national 
behavioral health care organizations, and  
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he served on the White House Health 
Review Group on Mental Health and 
Substance Abuse.  Dr. Forman is co-prin­
cipal investigator of the Delaware Valley 
Node of NIDA’s Clinical Trials Network. 
KEITH HUMPHREYS, Ph.D., is asso­
ciate professor of psychiatry at Stanford 
University School of Medicine in Stanford, 
California, and director of the Veterans 
Affairs Program Evaluation and Resource 
Center. He studies treatments and self-
help programs for substance abuse and 
psychiatric disorders and is actively involved 
in teaching addiction treatment methods 
to medical students, psychiatric residents, 
and clinical psychology interns. Dr. 
Humphreys has been a consultant to 
the White House Office on National Drug 
Control Policy, Center for Mental Health 
Services, National Institute on Alcohol 
Abuse and Alcoholism, and other Federal 
agencies. 
FRANKLIN W. INGRAM, M.Div., is 
executive director of SouthLight, a com­
munity addiction treatment program in 
Raleigh, North Carolina. SouthLight pro­
vides an extensive outpatient response to 
adolescents with substance abuse issues, 
whether court-ordered, school-ordered, 
or self-referred. Mr. Ingram has worked 
as a counselor with the Neighborhood 
Youth Corps and served as a social worker 
in child and adolescent counseling and 
family therapy. 
ANNE M. JOSEPH, M.D., M.P.H., is 
affiliated with the Transdiciplinary Tobacco 
Use Research Center at the University of 
Minnesota. She is the policy research direc­
tor and principal investigator for tobacco 
strategies for patients with cardiac disease. 
Dr. Joseph also serves as a general internist 
at the Minneapolis Veterans Affairs Medical 
Center. She has published numerous sci­
entific articles and abstracts on the topic 
of tobacco control, and she is a leader in 
statewide tobacco control efforts by the 
Minnesota Smoke-Free Coalition and the 
Minnesota Partnership for Action Against 
Tobacco. 
JENNIFER MANKEY, M.P.A., is exec­
utive director of the Center for Network 
Development in Denver, Colorado. She 
has 30 years’ experience with juvenile and 
adult offender programs and directed the 
Denver Juvenile TASC program and the 
Denver Juvenile Justice Integrated Treatment 
Network—two cross-sector collaborative 
projects that integrated treatment and 
juvenile justice strategies in order to improve 
outcomes for substance-abusing juvenile 
offenders. 
JOSEPH J. RICHARD, Jr., Ed.D., is staff 
psychologist at the Olympic Center-Preston, 
Inc., in Kingwood, West Virginia, a free­
standing, private, for-profit residential 
psychiatric treatment facility for substance-
dependent adolescents. At the Olympic 
Center he provides diagnosis and treat­
ment of psychological disorders, psycho­
logical consultation to the treatment team, 
safety risk management, behavior man­
agement, liaison to insurers, referral for 
psychiatric evaluation, and assistance with 
followup monitoring of target symptoms. 
He is also an adjunct assistant professor 
to West Virginia University and Marshall 
University. 
STEVEN SHOPTAW, Ph.D., is a prin­
cipal investigator with Friends Research 
Institute in Los Angeles and an associate 
research psychologist with the Integrated 
Substance Abuse Programs at UCLA. Over 
the past 10 years, Dr. Shoptaw has con­
ducted multiple phase 2 projects investi­
gating medication and behavior therapies 
for substance dependence. He recently 
completed a NIDA-funded study evalu­
ating behavioral therapies (relapse pre­
vention and contingency management, 
alone and in combination) for optimiz­
ing smoking cessation by tobacco smok­
ers in a methadone maintenance program. 
J. SCOTT TONIGAN, Ph.D., is the sen­
ior methodologist at the Center on 
Alcoholism, Substance Abuse and 
Addictions (CASAA) in Albuquerque, 
New Mexico, and has been involved in an 
11-year series of alcohol treatment out­
come trials, including Projects MATCH, 
CRAFT, ARTS, REPP, and COMBINE. 
Dr. Tonigan is currently supervising a 
10-year followup of the Albuquerque 
Project MATCH sample. He has a special 
interest in health disparity research in rela­
tion to treatment outcome and AA par­
ticipation. 
WILLIAM WENDT, J.D., CAC, is a co­
principal investigator for the Rocky 
Mountain Regional Node of NIDA’s 
Clinical Trials Network. He is also the 
CEO of Signal Behavioral Health Network, 
the largest managed services organization 
in Colorado. Mr. Wendt is an attorney 
and a certified addictions counselor with 
more than 15 years’ experience as a clini­
cian and administrator. 